Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine dilemma highlights DSHEA's faults, Food Advisory Committee members say.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE ALKALOID SAFETY ASSURANCE DIFFICULTIES HIGHLIGHT DSHEA's LIMITATIONS, committee member Bruce Chassy, PhD, University of Illinois at Urbana, suggested at an Aug. 27-28 meeting of FDA's Food Advisory Committee in Washington, D.C. The Dietary Supplement Health & Education Act is "from our normal perspective of regulating drugs, backwards," Chassy asserted. Under the act, "we put [a dietary supplement] on the market, we collect adverse reactions and when we've got enough of them, we take a look at them," he said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel